ACM
IOVA icon

ADAR1 Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

ADAR1 Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-50,000
Closed -$109K – 281
2025
Q3 		$109K Buy
+50,000
New +$118K 0.01% 200

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

ADAR1 Capital Management's IOVA Position: Q2 2026 in Review

ADAR1 Capital Management opened a new position in Iovance Biotherapeutics (IOVA) in Q2 2026: 146,090 shares worth $608K. The stake represents 0.03% of the portfolio and ranks #197 among its holdings. This is a return to the name: ADAR1 Capital Management previously reported a position in IOVA as recently as Q1 2025.

ADAR1 Capital Management first reported a position in IOVA in Q4 2023 and has held it in 7 quarters since. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • ADAR1 Capital Management held 146,090 shares of Iovance Biotherapeutics worth $608K as of Q2 2026.
  • Iovance Biotherapeutics was a new ADAR1 Capital Management position in Q2 2026.
  • Iovance Biotherapeutics made up 0.03% of ADAR1 Capital Management's portfolio in Q2 2026, its #197 holding.
  • ADAR1 Capital Management first reported a position in Iovance Biotherapeutics in Q4 2023 and has held it in 7 quarters since.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.